April
DEA's 2nd Annual Supply Chain Conference (April 30 - May 2, 2024)
Final Order: Placement of Etodesnitazene, N-Pyrrolidino Etonitazene, and Protonitazene in Schedule I (PDF) (April 11, 2024)
Proposed Rule: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I (PDF) (April 11, 2024)
Temporary Rule: Extension of Temporary Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I of the Controlled Substances Act (PDF) (April 11, 2024)
Announcement of Hearing: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (April 9, 2024)
VHG Labs dba LGC Standards (PDF) (April 9, 2024)
Lyndra Therapeutics (PDF) (April 9, 2024)
Traesa A. Brown, M.D.; Decision and Order (PDF) (April 5, 2024)
Ralph Reach, M.D.; Decision And Order (PDF) (April 5, 2024)
Sterling Wisconsin, LLC (PDF) (April 4, 2024)
Patheon Pharmaceuticals Inc. (PDF) (April 4, 2024)
Lonza Tampa, LLC (PDF) (April 4, 2024)
Benuvia Operations, LLC (PDF) (April 4, 2024)
Research Triangle Institute (PDF) (April 3, 2024)
Purisys, LLC (PDF) (April 3, 2024)
30-Day Notice: Drug Use Statement (PDF) (April 2, 2024)
March
Caligor Coghlan Pharma Services (PDF) (March 25, 2024)
Hybrid Pharma (PDF) (March 25, 2024)
Purisys, LLC (PDF) (March 25, 2024)
Stepan Company (PDF) (March 25, 2024)
SpecGx LLC (PDF) (March 25, 2024)
Restek Corporation (PDF) (March 25, 2024)
Halo Pharmaceutical Inc. (PDF) (March 25, 2024)
Promega Corporation (PDF) (March 25, 2024)
Usona Institute, Inc. (PDF) (March 25, 2024)
Sharp Clinical Services, LLC (PDF) (March 25, 2024)
Final Order: Placement of 2-Methyl AP-237 in Schedule I (PDF) (March 15, 2024)
Mark Fenzl, D.O.; Decision and Order (PDF) (March 11, 2024)
DEA and HHS Joint Letter on Medications for Opioid Use Disorder (MOUD) (PDF) (March 8, 2024)
Update: DEA Response to Change Healthcare Cyberattack (PDF) (March 7, 2024)
AndersonBrecon Inc. dba PCI Pharma Services (PDF) (March 6, 2024)
Sigma Aldrich Company LLC (PDF) (March 6, 2024)
Sterling Pharma USA LLC (PDF) (March 6, 2024)
Stepan Company (PDF) (March 6, 2024)
Nusachi Labs, LLC (PDF) (March 6, 2024)
Benuvia Operations, LLC (PDF) (March 6, 2024)
Organic Consultants LLC DBA Cascade Chemistry (PDF) (March 6, 2024)
DEA Response to Change Healthcare Cyberattack (PDF) (March 1, 2024)
February
Letter from DEA Administrator Anne Milgram: E-Comerce Platforms Selling Pill Press Machines (PDF) (February 26, 2024)
30-Day Notice: Automation of Reports and Consolidated Orders System (ARCOS) Transaction Reporting (PDF) (February 26, 2024)
30-Day Notice: Dispensing Records of Individual Practitioners (PDF) (February 26, 2024)
Siemens Healthcare Diagnostics Inc. (PDF) (February 23, 2024)
Meridian Medical Technologies, LLC (PDF) (February 23, 2024)
Pall Life Sciences PR, LLC (PDF) (February 23, 2024)
S&B Pharma LLC DBA Norac Pharma (PDF) (February 23, 2024)
Patheon API Services Inc. (PDF) (February 23, 2024)
Pfizer, Inc. (PDF) (February 23, 2024)
Janssen Pharmaceuticals Inc. (PDF) (February 23, 2024)
S&B Pharma LLC (PDF) (February 23, 2024)
Patheon API Services, Inc. (PDF) (February 23, 2024)
Henry Manning Pickett, M.D.; Default Decision and Order (PDF) (February 22, 2024)
January 2024
Final Rule: Conforming Amendment Regarding the Veterinary Medicine Mobility Act of 2014 (PDF) (February 8, 2024)
60-Day Notice: Drug Use Statement (PDF) (January 24, 2024)
Mylan Inc. (PDF) (January 23, 2024)
Mylan Pharmaceuticals, Inc. (PDF) (January 23, 2024)
Invizyne Technologies, Inc. (PDF) (January 23, 2024)
Medi-Physics Inc. DBA GE Healthcare (PDF) (January 23, 2024)
Myonex Inc. (PDF) (January 23, 2024)
Maridose, LLC (PDF) (January 23, 2024)
Arista Biologicals (PDF) (January 19, 2024)
Siegfried USA, LLC (PDF) (January 19, 2024)
Proposed Rule: Controlled Substance Destruction Alternatives to Incineration; Extension of Comment Period (PDF) (January 3, 2024)
December 2023
Advance Notice of Proposed Rulemaking: Controlled Substance Destruction Alternatives to Incineration - Extension of Comment Period (PDF) (December 20, 2023)
Joeseph Potter, D.D.S.; Decision and Order (PDF) (December 21, 2023)
Mark Young, M.D.; Decision and Order (PDF) (December 21, 2023)
Frank A. Hooper, D.V.M.; Decision and Order (PDF) (December 21, 2023)
Kinetochem LLC (PDF) (December 18, 2023)
Siegfried USA, LLC (PDF) (December 18, 2023)
AJNA BioSciences (PDF) (December 18, 2023)
Groff Health, Inc. (PDF) (December 18, 2023)
APEXX Pharmacy, LLC; Decision and Order (PDF) (December 15, 2023)
Gary R. Wisner, M.D.; Decision and Order (PDF) (December 15, 2023)
Proposed Rule: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (December 13, 2023)
Final Rule: Specific Listing for Three Currently Controlled Schedule I Substances (PDF) (December 13, 2023)
Temporary Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA into Schedule I (PDF) (December 12, 2023)
Placement of Nine Specific Fentanyl-Related Substances in Schedule I (PDF) (December 7, 2023)
Element Materials Technology Santa Rosa (PDF) (December 4, 2023)
Caligor Coghlan Pharma Services (PDF) (December 4, 2023)
Restek Corporation (PDF) (December 4, 2023)
November
Pharmaron Manufacturing Services (US) LLC (PDF) (November 30, 2023)
Pharmaron Manufacturing Services (US) LLC (PDF) (November 30, 2023)
Navinta LLC (PDF) (November 24, 2023)
Organix Chemistry Solutions, LLC (PDF) (November 24, 2023)
Groff NA Hemplex LLC (PDF) (November 24, 2023)
Organic Standards Solutions International, LLC (PDF) (November 24, 2023)
Isosciences, LLC (PDF) (November 24, 2023)
VHG Labs DBA LGC Standards (PDF) (November 24, 2023)
Sigma Aldrich Research Biochemicals, Inc. (PDF) (November 24, 2023)
Noramco (PDF) (November 8, 2023)
Noramco (PDF) (November 8, 2023)
Curia Missouri, Inc. (PDF) (November 8, 2023)
Jagjit Kaleka, D.V.M.; Decision and Order (PDF) (November 7, 2023)
Groff NA Hemplex LLC (PDF) (November 7, 2023)
Mylan Technologies Inc. (PDF) (November 7, 2023)
Osmin A. Morales, M.D.; Decision and Order (PDF) (November 2, 2023)
Isaac Sved, M.D.; Decision and Order (PDF) (November 2, 2023)
Blue Mint Pharmacy; Decision and Order (PDF) (November 2, 2023)
- REGISTRATION
- REPORTING
- RESOURCES
- CONTACT US
- PRIVACY NOTICE
- GET EMAIL UPDATES
Get Email Updates
The United States Department of Justice
You are now leaving a Department of Justice Web site.
You are about to access:
The Department of Justice does not endorse the organizations or views represented by this site and takes no responsibility for, and exercises no control over, the accuracy, accessibility, copyright or trademark compliance or legality of the material contained on this site.
Thank you for visiting our site.